BOSTON, MA --(Marketwired - September 03, 2015) - Pieris Pharmaceuticals, Inc . (
Mr. Yoder is scheduled to present on Wednesday, September 9th at 3:50 pm EDT. The presentation will be webcast live and available for replay at: http://wsw.com/webcast/rrshq25/pirs and on the investor relations section of the Company's website at www.pieris.com .
Institutional investors are also invited to request a one-on-one meeting with Pieris Pharmaceuticals management during the conference by emailing lk@rodmanevents.com or by contacting Pieris' investor relations team.
About Pieris Pharmaceuticals: Pieris is a clinical-stage biotechnology company advancing its proprietary Anticalin ® technology to create differentiated drugs that have the potential to be safer and more effective than conventional approaches. Anticalins show promise in addressing high-unmet medical needs and expanding the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. Anticalin ® , Anticalins ® are registered trademarks of Pieris. For more information visit www.pieris.com .
Forward Looking Statements: This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the timing of our clinical trials or other development efforts, references to novel technologies and methods; our business and product development plans; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov , including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014, and the Company's Quarterly Reports on Form 10-Q.
Company Contact: Pieris Pharmaceuticals, Inc. Darlene Deptula-Hicks SVP & Chief Financial Officer +1-603-553-5803 deptula@pieris.com Investor Relations Contact: The Trout Group Thomas Hoffmann +1-646-378-2931 thoffmann@troutgroup.com Media Inquiries: Gretchen Schweitzer +49 172 861 8540 gschweitzer@macbiocom.com The Del Mar Consulting Group, Inc. Robert Prag President +1-858-794-5000 bprag@delmarconsulting.com
